Table 1 Characteristics of patients with neuroblastoma in the training cohort and validation cohort
Characteristics | All Patients (n = 104) | Training cohort (n = 74) | Validation cohort (n = 30) | p value |
|---|---|---|---|---|
MYCN gene status | 0.263 | |||
Amplified | 65 (62.5%) | 41 (55.4%) | 24 (80.0%) | |
Not Amplified | 39 (37.5%) | 33 (44.6%) | 6 (20.00%) | |
Clinical factors | ||||
Age at diagnosis | 0.828 | |||
≥ 18 mos at diagnosis | 80 (76.9%) | 56 (75.7%) | 24 (80.0%) | |
< 18 mos at diagnosis | 24 (23.1%) | 18 (24.3%) | 6 (20.0%) | |
Gender | 0.541 | |||
Female | 62 (59.6%) | 46 (62.2%) | 16 (53.3%) | |
Male | 42 (40.4%) | 28 (37.8%) | 14 (46.7%) | |
High NSE (> 16.3 ng/mL) | 103 (99.0%) | 73 (98.7%) | 30 (100.0%) | 1.000 |
Normal NSE(≤ 16.3 ng/mL) | 1 (1.0%) | 1 (1.3%) | 0 (0.0%) | |
High SF (> 115 ng/mL) | 49 (47.1%) | 32 (43.2%) | 17 (56.7%) | 0.305 |
Normal SF(≤ 115 ng/mL) | 55 (52.9%) | 42 (56.8%) | 13 (43.3%) | |
High LDH(> 662.5 U/L) | 36 (34.6%) | 24 (32.4%) | 12 (40.0%) | 0.612 |
Normal LDH(≤ 662.5 U/L) | 68 (65.4%) | 50 (67.6%) | 18 (60.0%) | |
High VMA (> 68.6 μmo/L) | 70 (67.3%) | 50 (67.6%) | 20 (66.7%) | 1.000 |
Normal VMA(≤ 68.6 μmo/L) | 34 (32.7%) | 24 (32.4%) | 10 (33.3%) | |
High HVA(> 40 μmol/L) | 56 (53.8%) | 36 (48.7%) | 20 (66.7%) | 0.146 |
Normal HVA(≤ 40 μmol/L) | 48 (46.2%) | 38 (51.3%) | 10 (33.3%) | |
PET/CT radiological features | ||||
INRGSS | 0.920 | |||
L1, L2, MS | 39 (37.5%) | 42 (56.8%) | 16 (53.3%) | |
M | 65 (62.5%) | 32 (43.2%) | 14 (46.7%) | |
Thoracic primary | 1.000 | |||
Yes | 13 (12.5%) | 9 (12.2%) | 4 (13.3%) | |
No | 91 (87.5%) | 65 (87.8%) | 26 (86.7%) | |
Adrenal primary | 0.705 | |||
Yes | 73 (70.2%) | 52 (70.3%) | 21 (70.0%) | |
No | 31 (29.8%) | 22 (29.7%) | 9 (30.0%) | |
Infiltrating across midline | 0.473 | |||
Yes | 48 (46.2%) | 32 (43.2%) | 16 (53.3%) | |
No | 56 (53.8%) | 42 (56.8%) | 14 (46.7%) | |
Calcification | 0.200 | |||
Yes | 72 (69.2%) | 48 (64.9%) | 24 (80.0%) | |
No | 32 (30.8%) | 26 (35.1%) | 6 (20.0%) | |
Necrosis | 0.887 | |||
Yes | 77 (74.0%) | 54 (73.0%) | 23 (76.7%) | |
No | 27 (26.0%) | 20 (27.0%) | 7 (23.3%) | |
SUVmax (Median ± IQR) | 4.600 (3.8, 6.200) | 4.500 (3.625, 6.175) | 4.750 (4.225, 6.150) | 0.482 |
MTV (mL) (Median ± IQR) | 116.8 (40.2, 208.5) | 221.650 (73.700, 415.625) | 322.750 (137.050, 632.825) | 0.113 |
TLG (Median ± IQR) | 253.5 (81.6, 486.2) | 103.750 (39.475, 163.450) | 136.750 (48.600, 291.000) | 0.149 |